Lecanemab is now approved in Canada for treating early-stage Alzheimer’s disease, though clinical experts warn the benefits remain modest and the treatment process is resource-intensive. According to the Canadian Medical Association Journal (CMAJ), the medication requires specialized diagnostics and carries risks of serious adverse effects, necessitating careful shared decision-making between physicians, patients, and caregivers.
Why is the use of lecanemab considered complex?
The administration of lecanemab is not a simple prescription-based process. Dr. Sharon Straus, a geriatrician at Unity Health Toronto and professor, University of Toronto, notes that treatment requires a rigorous diagnostic framework to ensure patients are suitable candidates. Before starting, patients must undergo confirmation of amyloid buildup in the brain, typically through a PET scan or a lumbar puncture with cerebrospinal fluid analysis.
Once treatment begins, the process remains demanding. Patients require regular intravenous infusions and frequent monitoring via MRI scans. The monitoring is critical because the drug works by clearing amyloid from the brain, a process that can lead to side effects, including brain swelling and small brain bleeds.
What are the financial barriers to treatment?
Despite federal approval, access to lecanemab remains limited by its high cost. The drug is priced at about $35,000 to $40,000 per patient annually. Crucially, the medication is not currently publicly funded in Canada. According to the CMAJ report, most provinces and territories remain uncertain about whether they will cover it with health insurance, leaving many patients to face significant out-of-pocket expenses.
The authors of the CMAJ article emphasize that because clinical benefits are modest and carry potential risks, the decision to proceed should be individualized. Clinicians are encouraged to use tools to walk patients and their families through the trade-offs between potential delays in disease progression and the burden of frequent clinical monitoring.
How do clinicians weigh the risks and benefits?
The clinical community is balancing the drug’s potential against its limitations. Dr. Straus and her coauthors state that the interpretation of lecanemab’s benefits is often influenced by the limited availability of therapies and the personal and societal burdens of Alzheimer’s disease. However, the researchers caution that the actual impact on a patient’s long-term independence, quality of life, and caregiver burden remains uncertain.
For some patients, the possibility of delaying disease progression justifies the financial and physical requirements. For others, the CMAJ authors suggest that deferring treatment while waiting for further evidence may be a reasonable approach.
Frequently Asked Questions
- Who is eligible for lecanemab in Canada?
Patients with early Alzheimer’s disease who have confirmed amyloid in the brain are eligible for treatment. - Is lecanemab covered by Canadian provincial health insurance?
Currently, it is not publicly funded, and most provinces and territories remain uncertain about whether they will cover it. - What are the primary side effects of lecanemab?
Clinical monitoring is required to watch for brain swelling and small brain bleeds, which can occur as the medication clears amyloid protein.
Have you or a loved one been affected by the complexities of Alzheimer’s care? Join the conversation in the comments below or subscribe to our newsletter for the latest updates on medical research and health policy.
